In the present manuscript we will detail the first use of the Salen( t Bu)H 2 ligands with the group 13 elements. This includes the compounds of formula Salen( t Bu)AlCl (where Salen = Salen( N, N‘ -ethylenebis(3,5-di- tert -butylsalicylideneimine)) ( 1 ), Salpen ( N, N‘ -propylenebis(3,5-di- tert -butylsalicylideneimine)) ( 2 ), Salophen ( N, N‘ -benzenylidenebis(3,5-di- tert -butylsalicylideneamine)) ( 3 ), and Salomphen ( N, N‘ -(3,4-dimethylbenzenylidene)bis(3,5-di- tert -butylsalicylideneimine)) ( 4 )) and the novel five-coordinate monomeric amides of formula LAlNRR‘ (where L = Acen ( N, N‘ -ethylenebis(( t Bu)salicylidene(methyl)imine); R, R‘ = H, Ph ( 5 ); R = R‘ = SiMe 3 ( 6 )) and L = Salen (R, R‘ = H, t Bu ( 7 ), H, Ph ( 8 ), and H, Dipp (2,6-diisopropylphenyl) ( 9 ); R = R‘ = Me ( 10 ), Et ( 11 ), and SiMe 3 ( 12 ))). Additionally the unique monomeric hydroxy complex Salen( t Bu)AlOH ( 13 ) and its condensation product, (Salen( t Bu)Al) 2 O ( 14 ), will be described. All of the compounds were characterized by spectroscopic ( 1 H, 13 C, and 27 Al NMR, IR) and physical (mp, analyses) techniques. X-ray crystallographic data are presented for 14 .
No takes yet. Share an insight, caveat, or question.
Rutherford et al. (1996) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: